CY1116710T1 - Σκευασματα επικαλυμμενα με λεπτο υμενιο για χορηγηση απο στοματος που περιλαμβανουν δαποξετινη και ταδαλαφιλη - Google Patents

Σκευασματα επικαλυμμενα με λεπτο υμενιο για χορηγηση απο στοματος που περιλαμβανουν δαποξετινη και ταδαλαφιλη

Info

Publication number
CY1116710T1
CY1116710T1 CY20151100825T CY151100825T CY1116710T1 CY 1116710 T1 CY1116710 T1 CY 1116710T1 CY 20151100825 T CY20151100825 T CY 20151100825T CY 151100825 T CY151100825 T CY 151100825T CY 1116710 T1 CY1116710 T1 CY 1116710T1
Authority
CY
Cyprus
Prior art keywords
tadalafil
dopoxetine
posology
coated copper
administration containing
Prior art date
Application number
CY20151100825T
Other languages
English (en)
Inventor
Ali Türkylmaz
Gülay Yelken
Original Assignee
Sanovel Ilac Sanayi Ve Ticaret A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi Ve Ticaret A.S. filed Critical Sanovel Ilac Sanayi Ve Ticaret A.S.
Publication of CY1116710T1 publication Critical patent/CY1116710T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Abstract

Η παρούσα εφεύρεση αναφέρεται σε ένα σκεύασμα που περιλαμβάνει ένα συνδυασμό δαποξετίνης ή ενός φαρμακευτικά αποδεκτού άλατος αυτής και ταδαλαφίλη ή ενός φαρμακευτικά αποδεκτού άλατος αυτής. Η παρούσα εφεύρεση επίσης αναφέρεται σε μια διαδικασία για την παρασκευή αυτού του σκευάσματος και στην χρήση αυτού στην θεραπεία της πρόωρης εκσπερμάτισης που σχετίζεται με την στυτική δυσλειτουργία.
CY20151100825T 2012-08-17 2015-09-21 Σκευασματα επικαλυμμενα με λεπτο υμενιο για χορηγηση απο στοματος που περιλαμβανουν δαποξετινη και ταδαλαφιλη CY1116710T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TR201209599 2012-08-17
TR201212850 2012-11-07
EP13180694.5A EP2698147B1 (en) 2012-08-17 2013-08-16 Oral Film Formulations Comprising Dapoxetine and Tadalafil

Publications (1)

Publication Number Publication Date
CY1116710T1 true CY1116710T1 (el) 2017-03-15

Family

ID=48953339

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100825T CY1116710T1 (el) 2012-08-17 2015-09-21 Σκευασματα επικαλυμμενα με λεπτο υμενιο για χορηγηση απο στοματος που περιλαμβανουν δαποξετινη και ταδαλαφιλη

Country Status (11)

Country Link
US (1) US20150202168A1 (el)
EP (1) EP2698147B1 (el)
CY (1) CY1116710T1 (el)
DK (1) DK2698147T3 (el)
ES (1) ES2549224T3 (el)
HU (1) HUE027638T2 (el)
PL (1) PL2698147T3 (el)
PT (1) PT2698147E (el)
RS (1) RS54238B1 (el)
SI (1) SI2698147T1 (el)
WO (1) WO2014027980A1 (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015025859A2 (pt) * 2013-04-11 2017-07-25 Ctc Bio Inc forma de dosagem de filme contendo base livre de tadalafila contendo polímero à base de polietilenoglicol e/ou polímero à base de vinilpirrolidona como estabilizador de dispersão
US11116769B2 (en) 2013-04-11 2021-09-14 Ctc Bio, Inc. Tadalafil free base-containing film dosage form containing polyethylene glycol-based polymer and/or vinyl pyrrolidone-based polymer as dispersion stabilizer
ES2699160T3 (es) 2014-06-24 2019-02-07 Wooshin Labottach Co Ltd Formulación de película de desintegración oral que contiene tadalafilo y procedimiento de preparación de la misma
US20180280302A1 (en) * 2015-01-20 2018-10-04 Merck Patent Gmbh Solid dispersions of compounds using polyvinyl alcohol as a carrier polymer
IL247161A0 (en) * 2016-08-08 2016-12-29 Rubin Yoram Fast-dissolving adhesive films for the treatment of oral conditions
TR201715231A2 (tr) * 2017-10-09 2019-04-22 Montero Gida Sanayi Ve Ticaret Anonim Sirketi Dapokseti̇n ve fosfodi̇esteraz ti̇p-5 i̇nhi̇bi̇törü i̇çeren farmasöti̇k kombi̇nasyon
EP3723743A4 (en) * 2017-12-15 2021-09-08 Montero Gida Sanayi Ve Ticaret Anonim Sirketi DRUG COMBINATION INCLUDING DAPOXETINE, PHOSPHODIESTERASE TYPE 5 INHIBITOR AND ANTIEMETIC AGENT
US10653634B1 (en) * 2019-12-18 2020-05-19 King Abdulaziz University Polymeric nanoparticulate formulation to enhance the oral bioavailability of dapoxetine
US11147765B1 (en) * 2020-07-21 2021-10-19 King Abdulaziz University Instantly dissolving buccal films
US10973760B1 (en) 2020-07-21 2021-04-13 King Abdulaziz University Instantly dissolving buccal films
CN113908141B (zh) * 2021-12-01 2024-02-02 杭州成邦医药科技有限公司 一种氨溴索新型组合物及其制备方法
CN115645540A (zh) * 2022-12-22 2023-01-31 北京中科利华医药研究院有限公司 一种他达拉非喷雾剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT87163B (pt) 1987-04-09 1992-07-31 Lilly Co Eli Processo para a preparacao de 1-fenil-3-naftaleniloxi-propanaminas
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
CA2612917A1 (en) 2005-06-23 2007-01-04 Schering Corporation Rapidly absorbing oral formulations of pde5 inhibitors
CN101143145B (zh) * 2006-09-11 2011-11-09 黑龙江大学 他达拉非口香糖及制作方法和应用
EP2167048B1 (en) * 2007-05-30 2016-10-26 Wockhardt Limited A novel tablet dosage form
US20090004254A1 (en) * 2007-06-19 2009-01-01 Todd Maibach Film comprising active drugs
US20090047330A1 (en) * 2007-08-17 2009-02-19 Ramesh Bangalore Oral fast dissolving films for erectile dysfunction bioactive agents
US20100247586A1 (en) * 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
EP2316435A1 (en) * 2009-10-22 2011-05-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of PDE-5 inhibitors and dapoxetine
US20110136815A1 (en) * 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US20110263606A1 (en) * 2010-04-26 2011-10-27 Horst Zerbe Solid oral dosage forms comprising tadalafil

Also Published As

Publication number Publication date
US20150202168A1 (en) 2015-07-23
PL2698147T3 (pl) 2015-12-31
PT2698147E (pt) 2015-10-20
HUE027638T2 (en) 2016-11-28
DK2698147T3 (en) 2015-09-28
RS54238B1 (en) 2015-12-31
WO2014027980A1 (en) 2014-02-20
EP2698147A1 (en) 2014-02-19
ES2549224T3 (es) 2015-10-26
EP2698147B1 (en) 2015-07-22
SI2698147T1 (sl) 2015-11-30

Similar Documents

Publication Publication Date Title
CY1116710T1 (el) Σκευασματα επικαλυμμενα με λεπτο υμενιο για χορηγηση απο στοματος που περιλαμβανουν δαποξετινη και ταδαλαφιλη
CY1124311T1 (el) Παρεμποδιστες dna-pk
DOP2023000077A (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
CY1120730T1 (el) Απο του στοματος χορηγουμενη δοσολογια ενωσεων glp-1
CY1123953T1 (el) Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης
EA201891186A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
SV2016005257A (es) Benzimidazol-2-aminas como inhibidores de midh1
CL2014003444A1 (es) Compuestos derivados tienopirimidina; proceso de preparacion; composicion farmaceutica que los comprende; combinacion farmaceutica; uso en el tratamiento de canceres y enfermedades autoinmunes.
PE20151499A1 (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico
EA201390203A1 (ru) Способы получения тубулизинов
CY1121999T1 (el) Φαρμακοτεχνικες μορφες συνδυασμου δαρουναβιρης
CY1118074T1 (el) Ανθελονοσιακοι παραγοντες
CY1117620T1 (el) Τριτοκαλινη για χρηση στην αντιμετωπιση της κυστικης ινωσης
CY1121123T1 (el) Ενωσεις 6,7-διυδροπυραζολο[1,5-α]πυραζιν-4(5η)-ονης και η χρηση τους ως αρνητικοι αλλοστερικοι τροποποιητες των υποδοχεων mglu2
CY1124041T1 (el) Συνθεσεις που περιλαμβανουν κυκλοσπορινη
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
GT201400050A (es) Derivados de anilina, su preparación y su aplicación terapéutica
PH12016501686A1 (en) Pharmaceutical compositions of sitagliptin
GT201700016A (es) [1,2,4] triazolo [4,3 -b] piridazinas para su uso en el tratamiento de enfermedades proliferativas
CO2018012180A2 (es) Métodos de tratamiento para enfermedades colestásicas y fibróticas
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
EA201690974A1 (ru) Гидроморфон и налоксон для лечения боли и индуцированного опиоидами синдрома дисфункции кишечника
CL2017000884A1 (es) Composición farmacéutica para usarse en el tratamiento o la prevención de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugía de derivación gástrica
CY1124744T1 (el) Παραγωγα ιμιδαζοπυριδινης και η χρηση αυτων ως φαρμακο
CY1118913T1 (el) Νεοι ανθελονοσιακοι παραγοντες